In a significant milestone from around the medtech industry, Distalmotion recently announced that their Dexter robot has surpassed 1,000 successful surgical procedures. The Dexter robot, known for its compact and modular design, has demonstrated significant traction in European hospitals and ambulatory surgery centers since its initial commercial rollout in 2022. With utilization across complex and high-volume procedures in general surgery, gynecology, urology, Dexter has shown to be particularly adept at handling a broad range of soft tissue procedures and workflows.
Analyst Insights: Making robotic surgery more accessible
While Distalmotion continues to scale in Europe, the company is accelerating its path towards FDA approval with their 150 million dollar (USD) financing announced in April 2023. The market potential for soft tissue procedures in the United States is substantial. According to LSI’s Global Procedure Volumes Database, nearly 40 million soft tissue procedures were performed in the US in 2023. This figure represents approximately 43% of all surgical procedures conducted in the country. Of these nearly 40 million procedures, 23 million fall under the category of general surgeries. The increasing adoption of robotics in these procedures is a testament to the growing accessibility of novel robotic systems to hospitals and ambulatory surgery centers (ASCs).
Dexter’s success is a clear indicator of this trend. As robotic systems become more accessible, their integration into the relevant procedure markets is accelerating. Dexter’s modularity and compactness provide a significant competitive advantage, particularly for ASCs. It can be easily incorporated into existing surgical workflows, reducing the need for extensive infrastructure modifications. This adaptability, combined with its broad application across various soft tissue procedures, positions Dexter as a standout solution in the medtech innovation landscape.
More on Distalmotion
Distalmotion is gaining recognition as one of the most promising medtech companies in the field. The company participated at LSI USA ’24, the premier US based medtech conference bringing together hundreds of early and growth-stage medtech companies, venture investors, and decision-makers from global strategic partners.
Presentations by Greg Roche, CEO of Distalmotion, Greg Roche, on making robotic surgery more accessible and “The Stratification of Surgical Robotics: The Right Equipment in the Right Place for the Right Patient” can be found at the links below, alongside thousands of proprietary presentations available on our website and Youtube channel:
- Distalmotion presentation at LSI USA ‘24
- Distalmotion panel: The Stratification of Surgical Robotics: The Right Equipment in the Right Place for the Right Patient
Deeper profiles on Distalmotion and its competitors are available in our Companies & Deals database. This database provides detailed profiles of over 6,000 medtech companies, including associated deals, executive summaries, financing status, and proprietary presentations from the LSI emerging medtech summit. Visit our website to learn more about our Companies & Deals database and the full suite of medtech intelligence solutions available.
